Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.
The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82 per share. The company's net income for the quarter stood at $45.3 million, with an adjusted EBITDA of $61.4 million.
Notably, Penumbra's U.S. market performance was particularly strong, with revenue rising 19.5% and accounting for 76.8% of total revenue. The company's U.S. thrombectomy revenue saw a robust increase of 22.6%, while U.S. VTE revenue surged by an impressive 42% compared to the same period last year. In light of these strong results, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth of 20% to 21% compared to 2024 levels, further boosting investor confidence in its growth prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.